NEW YORK (GenomeWeb) – Cepheid reported after the close of the market Tuesday a 10 percent spike in third quarter revenues as the firm missed analysts' consensus estimates on both the top and bottom lines due primarily to lower-than-expected gross margin.

The firm also announced that the US Food and Drug Administration has approved its assay for Trichomonas vaginalis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.